Shots: Ionis to get $75M upfront plus $684M as development, regulatory, sales milestones, license fees and to receive tiered royalties up to 20% on sales. Ionis will be responsible for […]readmore
Tags : Develop
Shots: Collaboration is for development of novel drugs utilizing B. longum as a drug delivery carrier for in-situ Delivery and Production System (i-DPS) Technology. Astellas has option rights to further […]readmore
Shots: Verastem will receive an upfront of $15M with up to $30M for development milestones, additional sales milestones and double-digit royalties on net sales of Copiktra (duvelisib) CSPC to get […]readmore
Shots: The total acquisition value is based on option and share agreement i.e. EUR 210M signed in 2016 b/w two companies. Under the deal ViraTherapeutics will operate in Innsbruck, Austria […]readmore
Shots: Gilead will be paying Precision $445M as a milestone payment at specific development stages in addition to the double digit royalties (<19%) from sales Under the agreement, Precision will […]readmore
Shots: Elevian generated a seed funding of $5.5M from investors including WTI, Stanford StartX, Longevity Fund, Kizoo Ventures, Thynk Capital among others Its founders focus on regenerative effects of young […]readmore
Shots: Bluebird and Gritstone collaborated to research, develop and commercialize products to treat multiple cancer using cell therapies. Gritstone will provide 10 tumor-specific targets and T-cell receptors (TCRs) in certain […]readmore
Shots: Pfizer is planning to pay $120M upfront along with $305M milestone payment BioNTech will also receive double-digit royalties post sales whereas, Pfizer acquires small stakes in BioNTech as part […]readmore
Shots: With this collaboration GSK plans improve target selection to develop “Precision Medicine” with better efficacy and safety To identify specific subgroups population to develop targeted treatments GSK is initially […]readmore